



Hypersecretion of prolactin by lactotroph cells of the anterior pituitary may lead to hyperprolactinemia in physiological, pathological and idiopat-
hic conditions. Most patients with idiopathic hyperprolactinemia may have radiologically undetected microprolactinomas, but some may present 
other causes of hyperprolactinemia described as macroprolactinemia. This condition corresponds to the predominance of higher molecular mass 
prolactin forms (big-big prolactin, MW > 150 kDa), that have been postulated to represent prolactin monomer complexed with anti-prolactin im-
munoglobulins or autoantibodies. The prevalence of macroprolactinemia in hyperprolactinemic populations between 15-46% has been reported. 
In the pathophysiology of macroprolactinemia it seems that pituitary prolactin has antigenicity, leading to the production of anti-prolactin autoan-
tibodies, and these antibodies reduce prolactin bioactivity and delay prolactin clearance. Antibody-bound prolactin is big enough to be confi ned to 
vascular spaces, and therefore macroprolactinemia develops due to the delayed clearance of prolactin rather than increased production. Although 
the clinical symptoms are less frequent in macroprolactinemic patients, they could not be diff erentiated from true hyperprolactinemic patients, on 
the basis of clinical features alone. Although gel fi ltration chromatography (GFC) is known to be the gold standard for detecting macroprolactin, the 
polyethylene glycol precipitation (PEG) method has off ered a simple, cheap, and highly suitable alternative. In conclusion, macroprolactinemia can 
be considered a benign condition with low incidence of clinical symptoms and therefore hormonal and imaging investigations as well as medical or 
surgical treatment and prolonged follow-up are not necessary.
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Introduction
Human prolactin (PRL) is a single polypeptide hor-
mone containing 198 amino acid residues identi-
fi ed in 1970. Prolactin synthesis and secretion by 
pituitary lactotroph cells is tonically suppressed by 
hypothalamic dopamine traversing the portal ve-
nous system to impinge on lactotroph D2 recep-
tors. Factors inducing prolactin synthesis and se-
cretion include estrogen, thyrotropin-releasing 
hormone (TRH), epidermal growth factor, and do-
pamine receptor antagonists. The stimulatory ef-
fect of PRL release in response to TRH appears 
rarely in cases of primary hypothyroidism. Long-
term or inadequately treated primary hypothy-
roidism can cause pituitary hyperplasia that may 
mimic a pituitary tumor. Hyperprolactinemia and 
enlargement of the pituitary gland due to thyroid 
failure can be reversed by treatment with L-thyrox-
ine. The homology of the amino acids sequence 
between the PRL molecule and both human 
growth hormone and human placental lactogen is 
remarkable. The structure is folded to form a glob-
ular shape and braced by the three disulfi de bridg-
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es. Heterogeneity in molecular size of the human 
PRL molecule has been described in the human pi-
tuitary and serum. PRL is synthesized as a prehor-
mone (MW 26 kDa) and after cleavage the result-
ing hormone is a monomeric isoform of PRL (little 
PRL, MW 23 kDa). This monomeric isoform is the 
major circulatory form accounting for 80-95% of 
the total PRL and it is known be both biologically 
and immunologically active in vivo. The other 
forms mainly include the dimeric (big PRL, MW 45-
60 Da) and the polymeric isoform (big-big PRL, 
MW > 150 Da) or macroprolactin. In normal sera 
the dimeric isoform makes up < 10% of the PRL 
present and the polymeric isoform accounts for a 
small but variable percentage of total PRL (1). 
These latter two forms are known to have lower 
biological activity. Human macroprolactin displays 
low biological activity via its homologous receptor 
tested in Nb2 and Ba/F-LLP bioassays (2). Macro-
prolactin is a PRL variant with reduced bioactivity 
towards its homologous receptor, and this altered 
bioactivity may contribute to the lower disease ac-
tivity and absence of symptoms related to human 
PRL in systemic lupus erythematosus patients (3). 
Hyperprolactinemia is the state of increased serum 
PRL concentration (> 20 mcg/L or > 580 mIU/L) 
and it most commonly results from physiological 
or pathological conditions that cause hypersecre-
tion of PRL by lactotroph cells. True hyperpro-
lactinemia is characterized by the presence of ex-
cess monomeric PRL in serum. Hypersecretion of 
monomeric PRL leads to the classical symptoms 
and signs of true hyperprolactinemia which in-
clude oligomenorrhea or amenorrhea, galactor-
rhea, and infertility in women, loss of libido and 
impotence in men, and in children delayed puber-
ty, galactorrhea, gynecomastia, and primary amen-
orrhea. Hyperprolactinemia occurs in 15-20% cas-
es of women with chronic anovulatory cycles. 
Macroprolactinemia is defi ned by the predomi-
nance of serum macroprolactin together with non-
pathologic monomeric PRL concentrations. Physi-
ological conditions associated with an increased 
PRL release include pregnancy, puerperium, nurs-
ing, stress, pain, physical exercises, coitus, noctur-
nal sleep, high-protein meals and late follicular 
and luteal phase of menstrual cycle. Pathological 
hyperprolactinemia may result from a lactotroph 
adenoma (prolactinoma), empty sella syndrome, 
intracranial tumors compressing the pituitary stalk 
or hypothalamus, dopamine receptor D2 antago-
nist and PRL stimulative drugs, repetitive mechani-
cal stimulation of breast, chest wall trauma, hepa-
torenal disease and primary hypothyroidism (4-6).
Nevertheless, despite an extensive clinical, hor-
monal and neuroradiological work-up, no cause 
can be found in some patients whose serum PRL 
concentration may remain elevated for a long 
time. Such patients are often categorized as hav-
ing so-called idiopathic hyperprolactinemia. They 
are often subjected to repeated radiological ex-
aminations to fi nd undetectable microadenomas, 
to a long-term treatment with dopaminergic 
agents (including bromocriptine, cabergoline, and 
quinagolide), and even to a surgical intervention. 
There is accumulating evidence that macropro-
lactinemia in which most circulating PRL forms 
large protein complexes (more than 150 kDa), is a 
major cause of idiopathic hyperprolactinemia. The 
patients with macroprolactinemia are clinically 
characterized by the lack of hyperprolactinemia-
related symptoms such as amenorrhea and galact-
orrhea (6,7). Although a smaller proportion of pa-
tients with macroprolactinemia have signs and 
symptoms of hyperprolactinemia, galactorrhea is 
present in 20%, oligo/amenorrhea in 45%, and pi-
tuitary adenomas in 20% (8). Because macropro-
lactinemia is a variable cause of hyperprolactine-
mia, routine screening for macroprolactin could 
eliminate unnecessary diagnostic testing and 
treatment. Although the macroprolactin screening 
does not completely avoid inappropriate clinical 
investigation or associated health-costs, the aver-
age cost in patients with true hyperprolactinemia 
is signifi cantly higher than in patients with macro-
prolactinemia. Therefore, the importance of prop-
er medical education and knowledge diff usion of 
the meaning of macroprolactinemia would be de-
sirable (9).
History
In the fi rst description Whittaker et al. in 1981 re-
ported an interesting case of hyperprolactinemia 
Biochemia Medica 2012;22(2):171–9
  173
Kasum M. et al. Macroprolactinemia
whose serum PRL was predominantly (90%) con-
sisting of big-big PRL (10). The clinical symptoms 
of hyperprolactinemia such as amenorrhea and 
galactorrhea were absent, with maintained fertility 
and spontaneous pregnancy was possible despite 
hyperprolactinemia. It was suggested that big-big 
PRL had a low receptor affi  nity that might account 
for the apparent lack of any biological eff ect. The 
predominance of the highest molecular size (150-
170 kDa) PRL in a woman who conceived following 
infertility was also demonstrated in 1982 by An-
derson et al. (11). They found the bioactivity of 
macroprolactin component in vitro and suggested 
that the absence of in vivo bioactivity might be the 
result of the big-big PRL complex preventing pas-
sage through the capillary endothelium to the tar-
get cell. Jackson et al. fi rst used the new term 
„macroprolactinemia“ in 1985 to describe a patient 
with a three-year history of documented serum 
PRL levels of 350 to 400 ng/mL presenting like a pi-
tuitary tumor, but with no evidence of a pituitary 
adenoma on computed axial tomographic scan-
ning (12). Analysis of circulating prolactin by col-
umn chromatography of the patient’s serum re-
vealed that greater than 85 percent of her circulat-
ing immunoreactive PRL had a molecular weight 
greater than 100 kDa. A reduced biological activity 
of macroprolactin (compared with monomeric 
PRL) was suggested as the reason for the lack of 
symptoms.
Prevalence
The proportion of macroprolactinemia in the gen-
eral population has previously been reported at 
0.2% in women and 0.02% in men (13). However, a 
recent study suggests that macroprolactinemia 
may be more common, with a prevalence of 3.68% 
and no diff erence in prevalence between genders. 
Approximately three quarters of the subjects with 
macroprolactinaemia had anti-prolactin autoanti-
bodies. Glycosylation, aggregation and covalent/
noncovalent binding were also involved in the for-
mation of macroprolactin (14). These data suggest 
that this condition represents an often overlooked 
diagnosis and a cause of hyperprolactinemia 
whose frequency is certainly underestimated. Re-
ported proportion of macroprolactinemia in hy-
perprolactinemic populations in most studies var-
ies between 15 and 35% (15,16). One study report-
ed a prevalence of 46%, but it is likely that this par-
ticular incidence refl ected selection bias because 
of the specialized nature of the study center, which 
received samples sent from other laboratories 
when the possible diagnosis of macroprolactine-
mia was raised (17).
Pathophysiology
Although macroprolactinemia is heterogeneous 
the condition is characterized by the predomi-
nance of circulating high molecular mass PRL 
forms which have coupled with anti-PRL immuno-
globulins. These autoantibodies have been found 
to be immunoglobulin (IgG) isotypes with low re-
ceptor affi  nity in vivo and they may be a primary 
cause of hyperprolactinemia. Although macropro-
lactin has been shown to exhibit varying degrees 
of biological activity in vitro, because of its high 
molecular mass the complex is confi ned to the 
vascular system in vivo and hence is bio-unavail-
able. Its high molecular weight may reduce its ac-
cess to target organs in the periphery as well as 
centrally (11,12,18). Mechanisms involved in the de-
velopment of anti-PRL antibodies are still un-
known. A speculation on the source of these anti-
bodies suggests that posttranslational modifi ca-
tions (glycosylation and phosphorylation) of some 
proteins and PRL may create neo-epitopes (anti-
body-binding sites on the PRL molecule) for the 
production of antibodies (19). Hattori et al. have re-
cently reported by examining IgG subclasses of 
the antibodies that the predominant form was 
IgG4 (20). Because IgG4 usually plays an important 
role in allergic conditions, it was suggested that 
there may also be a chronic stimulation by PRL 
with possible altered antigenicity in patients with 
anti-PRL antibodies. Their data fi rst demonstrated 
that human pituitary PRL was serine phosphory-
lated and partially dephosphorylated in serum, 
suggesting that the acidic forms may give rise to 
chronic antigen stimulation in patients with anti-
PRL antibodies. If pituitary phosphorylated forms 
of PRL such as phosphorylated ones are intolerant 
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to the immune system, leakage of such forms of 
PRL upon hypophysitis or lack of dephosphoryla-
tion may cause an autoimune response. These 
fi ndings suggest that pituitary PRL, even if homol-
ogous, has antigenicity, leading to the develop-
ment of anti-PRL autoantibodies. Several possibili-
ties may be discussed for the cause of hyperpro-
lactinemia in patients with anti-PRL antibodies. A 
positive correlation was found between the titer 
of anti-PRL antibodies and serum PRL level, sug-
gesting that the autoantibodies were the cause of 
hyperprolactinemia. The clearance of PRL is slower 
in the presence of anti-PRL antibodies, suggesting 
that antibody-bound PRL is big enough to be con-
fi ned to vascular spaces, including the prevention 
of the bound PRL fi ltration from the glomerules. 
Therefore macroprolactinemia develops due to 
the delayed clearance of PRL rather than increased 
production. These autoantibodies reduce PRL bio-
activity and delay PRL clearance. Lastly, these PRL 
autoantibodies are stable with time, for at least 5 
weeks, what supports the idea that macropro-
lactinemia is a chronic condition in humans (21). 
During the metoclopramide test, dimeric and mo-
nomeric PRL levels increased and rapidly returned 
to the basal levels, whereas macroprolactin kept 
increasing. This may also contribute to the patho-
genesis of macroprolactinemia, due to a lack of 
negative feedback, because PRL-autoantibody 
complex cannot freely access the hypothalamus 
(22). Lack of macroprolactin in the pituitary tissue 
and in the extravascular space may be the reason 
for the absence of symptoms in the clinical presen-
tation. It was reported that epitopes of anti-PRL 
autoantibodies in patients with macroprolactine-
mia were located near binding site 1 to human PRL 
receptors, raising a possibility that anti-PRL au-
toantibodies may compete with the PRL molecule 
for binding to its receptors, resulting in reduced 
bioactivity in vivo and asymptomatic clinical pre-
sentation (23). However, studies on big-big PRL bi-
ological activity in vivo are still controversial. The 
controversy is largely a result of the fi nding of sub-
stantial numbers of patients with hyperprolactine-
mia attributable to macroprolactin and symptoms 
of the hyperprolactinemic syndrome (24,25). Suli-
man et al. argue that the symptoms and hyperpro-
lactinemia attributable to macroprolactin in these 
cases are coincidental, whereas Olukoga suggests 
that the macroprolactin complex may dissociate in 
vivo in some cases, releasing bioactive, monomeric 
PRL that causes the symptoms (16,26). It is, there-
fore, possible that increasing bioavailability of mo-
nomeric PRL due, perhaps, to intermittent dissoci-
ation from the low affi  nity, high capacity IgG anti-
body to which it is bound in macroprolactin, and/
or infl uence of macroprolactin in PRL secretion, 
may be a contributory factor to development of 
symptoms of PRL excess.
Clinical feature
The earliest reports of macroprolactinemia were 
isolated cases in patients being investigated for 
nonreproductive endocrine problems or healthy 
research volunteers who had no symptoms of hy-
perprolactinemia, but normal menstruation and 
maintained fertility (10,11). Subsequently, the con-
dition was suspected mainly when unexplained 
hyperprolactinemia was found without recog-
nized symptoms of PRL excess; this situation may 
have helped perpetuate the notion that macro-
prolactinemia is essentially asymtomatic (12). How-
ever, not all patients with macroprolactinemia lack 
clinical symptoms because in fi ndings of more re-
cent clinical studies a signifi cant proportion of pa-
tients appeared to suff er from symptoms com-
monly associated with true hyperprolactinemia 
(24,25). Symptoms related to PRL excess were 
found in about 44% of individuals from the macro-
prolactinemia group and in 88.5% of patients with 
monomeric hyperprolactinemia (25). Circumstanc-
es leading to the diagnosis of macroprolactinemia 
included menstrual disorders (39%), infertility 
(29%), galactorrhea (46%) (24). Although oligome-
norrhea/amenorrhea and galactorrhea were more 
common in patients with true hyperprolactinemia, 
macroprolactinemic patients could not be diff er-
entiated from true hyperprolactinemic patients on 
the basis of clinical features alone. Serum levels of 
estradiol and LH and the LH/FSH ratio were signifi -
cantly greater in macroprolactinemic compared 
with true hyperprolactinemic subjects. Because 
macroprolactinemia is a common cause of hyper-
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prolactinemia, routine screening of all hyperpro-
lactinemic sera for macroprolactin could eliminate 
unnecessary diagnostic testing and treatment (27). 
Therefore, no clinical features could reliably diff er-
entiate macroprolactinemic from true hyperpro-
lactinemic patients, because at least one of these 
symptoms was present in most macroprolactine-
mic patients (28). The possible association of 
macroprolactinemia with a pituitary tumor or
other causes of hyperprolactinemia warrants a 
cautious initial and subsequent work-up of pa-
tients with this disorder and clearly does not allow 
us to limit this diagnosis to the sole fi eld of idio-
pathic hyperprolactinemia (24). Although the prev-
alence of pituitary adenomas in macroprolactine-
mic patients is lower (26.7%) compared with the 
true hyperprolactinemic patients (55.4%), it may 
be higher than that found in other recent studies 
and in the general population (15-17,29-31).
Because true hyperprolactinemia and macropro-
lactinemia cannot be reliably distinguished on 
clinical criteria alone, a Task Force of The Endocrine 
Society suggested screening for macroprolactin in 
investigation of asymptomatic hyperprolactinemic 
subjects (32,33). Routine screening of all hyperpro-
lactinemic sera for macroprolactin is cost eff ective 
and could eliminate unnecessary diagnostic test-
ing and treatment (27).
Laboratory diagnosis
Laboratory techniques demonstrating hyperpro-
lactinemia are essential for the accurate diagnosis 
and treatment of patients. Nowadays, laboratory 
professionals are faced with challenging inabilities 
of the commercially available immunoassays to 
diff erentiate the patients with true hyperpro-
lactinemia, due to the increased serum levels of 
monomeric prolactin, from those with macropro-
lactinemia (21). Namely, macroprolactin is detect-
ed by all immunoassays, although to varying de-
grees (34,35). Generally, methods determining PRL 
have been declared as high-, medium- and low-
reading for macroprolactin (35). According to ear-
lier studies, the variability of immunoassays to de-
tect macroprolactin in the sample depends on the 
disposition of the epitopes on the PRL molecule 
towards the antibodies used in vitro (capture anti-
body), supposing that diff erent antigenic sites 
might be occupied by the diff erent endogenous 
human antibodies (autoantibodies) (35-37). De-
spite the comprehensive knowledge and eff orts to 
solve this analytical problem, manufacturers of im-
munoassays have failed to produce the antibody 
which would be directed against epitope specifi c 
only for monomeric PRL (38). Undoubtedly, good 
laboratory practice requires screening for macro-
prolactin in all hyperprolactinemic sera and deter-
mination of PRL concentrations after the removal 
of macroprolactin from pretreated samples. Sev-
eral separation techniques have been elaborated.
Gel fi ltration chromatography (GFC) has been con-
sidered the reference method for the separation 
of macroprolactin from mono- and dimeric PRL. 
Chromatographic gel retains the molecules by 
their diff erent molecular weight and three-dimen-
sional shape as they pass through a column (39). 
Although the technique of GFC is robust and re-
producible, some disadvantages preclude its wide-
spread use in diagnostic laboratories. First, a cer-
tain amount of PRL-autoantibody complex may 
dissociate during the lengthy chromatographic gel 
fi ltration run, thereby leading to an underestima-
tion of the macroprolactin in serum. Second, the 
estimation of the percentage of macroprolactin 
could be imprecise in the sequence of 30-40 dis-
crete fractions eluted from column. Third, adsorp-
tion or denaturation of immunoreactive material 
during the gel fi ltration procedure may be selec-
tive and cause the disproportionate loss of individ-
ual isoforms of PRL in treated sample. Fourth, and 
maybe the most important, GFC is time-consum-
ing, expensive technique that requires a consider-
able technical skill and therefore is more suitable 
for the research laboratories (34,39).
Separation of macroprolactin by immunoadsorp-
tion with Protein A (PA) and Protein G (PG), immo-
bilized on Sepharose, is based on high affi  nity of 
PA and PG for human IgG, which is a primary anti-
body to PRL in serum. After incubation, immuno 
complexes between PA or PG and macroprolactin 
in an aliquot of serum are precipitated by centrifu-
gation and the concentration of monomeric PRL is 
measured in supernatant. Although this method 
Biochemia Medica 2012;22(2):171–9
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exhibits acceptable precision and the recovery of 
standard preparation is satisfactory, some of the 
authors have shown that pretreatment of sera with 
PA and PG leads to a signifi cant overestimation of 
monomeric PRL concentrations (39,40). Such a di-
vergence of results from target limits the useful-
ness of this method for removal of macroprolactin 
from serum.
Separation of macroprolactin by means of ultrafi l-
tration is based on the passage of PRL through the 
separating membrane which selectively retains 
particles according to their molecular size, net 
charge and three-dimensional structure. Serum 
sample is diluted with phosphate buff ered saline 
(PBS) and subjected to a fi lter device and the unit 
is centrifuged at the recommended speed and the 
duration of time. Concentration of monomeric PRL 
is measured in ultrafi ltrated and original sample; 
results are then calculated as percentage of recov-
ery of PRL (41,42). Although, ultrafi ltration repre-
sents a practical and precise alternative to GFC for 
estimating the macroprolactin in serum, the PRL 
concentrations recorded after ultrafi ltration, com-
pared with those after GFC, may vary considerably 
from sample to sample (39,42).
Number of studies has shown that polyethylene 
glycol (PEG) induced precipitation of macroprolac-
tin in serum sample may represent a simple, acces-
sible and reproducible screening technique for hy-
perprolactinemic sera (43-45). Detailed description 
of PEG separation method has been reported by 
several authors (39,42,44,46). The method is based 
on diff erent precipitation of proteins according to 
their molecular weight and solubility in aqueous 
PEG solution. It has been generally accepted that 
PRL recovery of 40% of its initial value, after PEG 
treatment, indicates the presence of macroprolac-
tin in patient’s serum, although the thresholds 
vary between <30-50% (46,47). Precipitation with 
PEG is widely used screening test for macroprolac-
tin and is easily performed in clinical laboratories. 
However, PEG also induces a partial precipitation 
of monomeric PRL (up to 25%) so reliance on the 
relative percentage of recovery lacks specifi city 
which may lead to an underestimated evaluation 
and misinterpretation of actual PRL levels (39). This 
is especially important in cases when an excessive 
macroprolactin occurs in patient’s serum simulta-
neously with supraphysiological concentrations of 
monomeric PRL. Furthermore, it has been report-
ed that the presence of PEG in the sample can in-
terfere with some PRL immunoassay procedures 
(48). To avoid such problems, it has been recom-
mended that each laboratory, undertaking macro-
prolactin screening, has to establish method-spe-
cifi c reference intervals derived by use of PEG-
treated sera from healthy individuals (44-46). So, in 
routine laboratory diagnostics the post-PEG modi-
fi ed reference range is the best means to accurate-
ly identify patients with true hyperprolactinemia 
(46).
It is also worth to mention that the standardization 
of the PRL assays can contribute to the confusion 
when comparing results between various meth-
ods, because of the diff erent reference prepara-
tions and units in use. Concentrations of serum 
PRL have been expressed in mass (µg/L or ng/mL), 
molar (nmol/L or pmol/L) or international units 
(mIU/L). Most of the current assays have been cali-
brated against the Third International Standard for 
Prolactin (WHO 3rd IS 84/500). According to this 
standard preparation, 2.5 µg of lyophilized human 
PRL has been assigned as the activity of 0.053 In-
ternational Units of PRL. Concentration of 1 mIU/L 
can be converted to µg/L by dividing with 21.2 
(45). Some of the assays have been standardized 
against the 2nd IS 83/562 (49).
It seems unlikely that any of the techniques for 
macroprolactin determination can be used to 
screen all the samples analyzed in the clinical bio-
chemistry laboratory. In the reality, detection of 
macroprolactin and awareness of interferences, 
distinctive to particular methods, usually come out 
as a consequence of incongruity between bio-
chemical results and clinical validation. Still, for the 
accurate and early-stage diagnosis of macropro-
lactinemia clinical symptoms should be a starting 
point for clinical biochemists. On one side, it im-
plies a close communication between a laboratory 
and clinicians and on the other, manufacturers 
supplying the PRL immunoassays should incorpo-
rate all interference data, validated protocols and 
guidelines for macroprolactin screening. At the 
same time, it includes the assumption that labora-
Biochemia Medica 2012;22(2):171–9
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tories undertaking PRL analyses inform clinicians 
about the characteristics and limitations of the as-
say in use.
Conclusion
In today’s health care system the prevalence of 
medical errors of about 10% in clinical medical 
laboratories has been consistently reported. Most 
of these errors occur in the pre-analytical phase. 
Because only a small number of errors will be seen 
in the analytical phase, it is very likely that these 
might be very often ignored. The knowledge of 
analytical interferences and critical sample quality 
will off er valuable solutions to improve the global 
quality of the total testing process. The impact of 
errors in the analytical process will be better un-
derstood and the examples will help reducing the 
number of analytical errors and interferences, so 
that a much better patient safety can be granted 
(50). This article shows how important is a good 
communication between laboratory and clinician. 
Both laboratory professionals and clinicians should 
continuously aim to reduce medical errors and en-
hance patient safety by minimizing the risk of pa-
tient misdiagnosis. The knowledge of the ways to 
diagnose and interpret macroprolactinemia means 
benefi t for the patient safety. All the patients with 
hyperprolactinenia radiographic data incompati-
ble with their PRL levels with no regard to clinical 
symptoms should be routinely screened for the 
presence of macroprolactin to avoid unnecessary 
investigations, incorrect diagnosis and inappropri-
ate dopamine agonist treatment. However, when 
excess macroprolactin occurs simultaneously with 
increased concentrations of monomeric PRL the 
priority for the laboratory should be to determine 
whether the bioactive monomeric PRL concentra-
tion is increased rather than simply to measure the 
percentage of macroprolactin present. The pres-
ence of excess monomeric prolactin is of overrid-
ing concern, and a diagnosis of macroprolactine-
mia in this setting is misleading and inappropriate. 
However, the patients with macroprolactinemia 
and normal concentrations of monomeric PRL 
would cause less anxiety and they can be reas-
sured without extented investigations during pro-
longed follow-up. It is unavoidable to alert endo-
crinologists, gynecologists, pharmacologists and 
also general practioners and all those involved in 
the management of hyperprolactinemia to macro-
prolactin, its frequent occurrence and its timely 
recognition.
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Makroprolaktinemija: novi uvidi u hiperprolaktinemiji
Sažetak
Pojačana sekrecija prolaktina od strane laktotropnih stanica adenohipofi ze dovodi do hiperprolaktinemije u fi ziološkim, patološkim i idiopatskim 
stanjima. Kod većine bolesnica s idiopatskom hiperprolaktinemijom radiološki se ne otkrivaju mikroprolaktinomi, a kod nekih se nalaze dru-
gi razlozi hiperprolaktinemije pod nazivom makroprolaktinemija. Ovakvom stanju najviše pridonosi visoko molekularni oblik prolaktina (veliki 
prolaktin, Mr 50 kDa i uglavnom veliki-veliki prolaktin, Mr > 150 kDa), za kojeg se pretpostavlja da ga čine monomeri prolaktina spojeni s anti-
prolaktinskim imunoglobulinima ili protutijelima. Pojavnost makroprolaktinemije kreće se između 15-46% u populaciji s hiperprolaktinemijom. 
U patofi ziologii makroprolaktinemije čini se da prolaktin iz adenohipofi ze ima antigenost, koja dovodi do stvaranja antiprolaktinskih protutijela 
koji prolaktinu smanjuju bioaktivnost i usporavaju klirens. Kako je spoj prolaktina i protutijela dostatno velik ograničen je na vaskularni prostor te 
stoga nastaje makroprolaktinemija prije zbog usporenog klirensa nego pojačanog stvaranja. Iako su klinički simptomi rjeđi u bolesnica s makro-
prolaktinemijom ne mogu se razlikovati od bolesnica s pravom hiperprolaktinemijom samo na temelju kliničke slike. Premda se kromatografska 
fi ltracija gelom (GFK) smatra zlatnim standardom u detekciji prolaktina, ipak metoda precipitacije polietilen glikolom (PEG) predstavlja jedno-
stavnu, jeftinu i visoko prikladnu metodu. Zaključujemo da se makroprolaktinemija može smatrati benignim stanjem s malom pojavnošću klinič-
kih simptoma zbog čega su nepotrebne hormonske i radiološke pretrage, a isto tako medikamentozno i kirurško liječenje i dugotrajno praćenje.
Ključne riječi: makroprolaktin; dijagnoza; klinička slika; patofi ziologija
